Geodon (Ziprasidone) for Posttraumatic Stress Disorder
Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
Atypical antipsychotics have shown promise in the treatment of depression and anxiety, which
are prominent symptoms of PTSD. The profile of the atypical antipsychotic, ziprasidone
(Geodon), suggests possible anxiolytic and antidepressant properties. This research will
assess the potential effectiveness of Geodon in civilian men and women who suffer from severe
PTSD. Response to ziprasidone or placebo will be measured by Clinician Administered PTSD
Scale (CAPS) and Treatment Outcomes PTSD Scale (TOP-8).